Establishing a pipeline of next generation first- and best-in-class therapies to address the significant unmet medical needs in obesity and related metabolic conditions, helping patients to achieve and maintain healthier weight loss
Asset
Preclinical
Phase 1
Phase 2
GLP-1 antibody–peptide fusion protein (ALV-100)
Obesity
AMYR3 agonist
Amylin small molecule
Quarterly injectable GLP1 mono agonist
Undisclosed
With unwavering scientific excellence, quality, respect for others, we build trust and long-lasting relationships
